| 000 | 01714 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518074816.0 | ||
| 264 | 0 | _c20200706 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a2052-1707 | ||
| 024 | 7 |
_a10.1002/prp2.552 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPérez, Angela V | |
| 245 | 0 | 0 |
_aEvaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE. _h[electronic resource] |
| 260 |
_bPharmacology research & perspectives _c12 2019 |
||
| 300 |
_ae00552 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 |
_aColombia _xepidemiology |
| 650 | 0 | 4 |
_aCost Savings _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDelivery of Health Care _xeconomics |
| 650 | 0 | 4 |
_aDrug Costs _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aDrug Industry _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGroup Purchasing _xeconomics |
| 650 | 0 | 4 | _aHealth Plan Implementation |
| 650 | 0 | 4 |
_aHepacivirus _xisolation & purification |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNegotiating |
| 650 | 0 | 4 | _aPolicy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aProgram Evaluation |
| 650 | 0 | 4 | _aStakeholder Participation |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTrujillo, Antonio J | |
| 700 | 1 | _aMejia, Aurelio E | |
| 700 | 1 | _aContreras, Johnny D | |
| 700 | 1 | _aSharfstein, Joshua M | |
| 773 | 0 |
_tPharmacology research & perspectives _gvol. 7 _gno. 6 _gp. e00552 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/prp2.552 _zAvailable from publisher's website |
| 999 |
_c30440881 _d30440881 |
||